Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
GlobalData on MSN3d
Daiichi Sankyo doses first subject in Phase III AML therapy trial
Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...
Moleculin Evaluates Prelim. Activity Of Annamycin In Acute Ara-C, VEN Resistant Myeloid Leukemia
(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...
QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML
The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s (TSE: 4568) VANFLYTA® ...
What's Going On With Moleculin Biotech Shares Wednesday?
Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical ...
The American Journal of Managed Care14d
New CPX-351 Data Underscore Complexity of Treating AML in Older Patients
Phase 2 data show about half of patients with high-risk or secondary acute myeloid leukemia achieved a complete response or ...
Cancer Therapy Advisor7d
Approach Produces “Excellent” CRc Rate in Newly Diagnosed AML
Triplet induction with alternating consolidation regimens appeared to be effective in patients with newly diagnosed AML, according to researchers.
Nature5y
Bcl-2 antisense therapy shows promise in older patients with acute myeloid leukemia
Patients received induction chemotherapy with oblimersen, cytarabine and daunorubicin. Further doses of oblimersen and high-dose cytarabine were administered as consolidation treatment in the ...